Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Human CYP3A4 Anticorps:
anti-Mouse (Murine) CYP3A4 Anticorps:
anti-Rat (Rattus) CYP3A4 Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Human Polyclonal CYP3A4 Primary Antibody pour IHC (p), WB - ABIN514838
Yamashita, Honda, Nio, Nakamoto, Yamashita, Takamura, Tani, Zen, Kaneko: Oncostatin m renders epithelial cell adhesion molecule-positive liver cancer stem cells sensitive to 5-Fluorouracil by inducing hepatocytic differentiation. dans Cancer research 2010
Show all 3 Pubmed References
Human Monoclonal CYP3A4 Primary Antibody pour ICC, FACS - ABIN969512
van Waterschoot, Rooswinkel, Sparidans, van Herwaarden, Beijnen, Schinkel: Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam. dans Drug metabolism and disposition: the biological fate of chemicals 2009
Show all 2 Pubmed References
Human Polyclonal CYP3A4 Primary Antibody pour Func, WB - ABIN2473177
Chirkov YuYu, Tyshchuk, Severina: Guanylate cyclase in human platelets with different aggregability. dans Experientia 1990
Show all 3 Pubmed References
Cow (Bovine) Polyclonal CYP3A4 Primary Antibody pour WB - ABIN2784528
Werk, Lefeldt, Bruckmueller, Hemmrich-Stanisak, Franke, Roos, Küchle, Steubl, Schmaderer, Bräsen, Heemann, Cascorbi, Renders: Identification and characterization of a defective CYP3A4 genotype in a kidney transplant patient with severely diminished tacrolimus clearance. dans Clinical pharmacology and therapeutics 2014
Human Polyclonal CYP3A4 Primary Antibody pour WB - ABIN514839
De Bock, Colin, Boussery, Van Bocxlaer: Development and validation of an enzyme-linked immunosorbent assay for the quantification of cytochrome 3A4 in human liver microsomes. dans Talanta 2012
Human Polyclonal CYP3A4 Primary Antibody pour WB - ABIN269568
Buchanan, Meng, Poulin, Zuccolo, Azike, Gabriele, Baranowski: Comparative pharmacokinetics and safety assessment of transdermal berberine and dihydroberberine. dans PLoS ONE 2018
Human Polyclonal CYP3A4 Primary Antibody pour ELISA - ABIN547650
Choi, Skipper, Wishnok, Tannenbaum: Characterization of testosterone 11 beta-hydroxylation catalyzed by human liver microsomal cytochromes P450. dans Drug metabolism and disposition: the biological fate of chemicals 2005
Human Polyclonal CYP3A4 Primary Antibody pour IF, IHC - ABIN3023346
Wei, Dai, Zhou, He, Yao, Zhao, Guo, Yang: Oroxylin A activates PKM1/HNF4 alpha to induce hepatoma differentiation and block cancer progression. dans Cell death & disease 2018
Human Polyclonal CYP3A4 Primary Antibody pour IP, WB - ABIN947776
Fujiwara, Itoh: Extensive protein interactions involving cytochrome P450 3A4: a possible contributor to the formation of a metabolosome. dans Pharmacology research & perspectives 2014
FLCWK up-regulates CYP3A4 levels via the PXR pathway.
In a Spanish population treated with paclitaxel, none were carriers of the CYP3A4*20 variant that may predict paclitaxel-induced neuropathy.
The characterization of CYP3A4*1B and 3435C>T MDR1 polymorphism cannot provide useful guidance for individualizing cyclosporine A dosages in renal transplant patients by indicating the optimal dose of these drugs without exposing patients to possible adverse effects associated mainly with nephrotoxicity.
CYP3A4*1G/CYP3A4*1G genotype may be associated with poor prognosis at 1 year after acute ischemic stroke in the Han Chinese population.
CYP3A4 protein expression was significantly lower in diabetes mellitus, nonalcoholic fatty liver disease (NAFL), and nonalcoholic steatohepatitis (NASH) donors and accounted for significant midazolam hydroxylation variability. Predicted midazolam exposure was 1.7- and 2.3-fold higher for NAFL and NASH, respectively, which may result in a longer period of sedation in these disease-states.
CYP3A4 allele did not affect severe irinotecan-induced toxicity in irinotecan-treated colorectal cancer patients.
CYP3A4 genetic variants were not associated with treatment resistance when compared to responders to clopidogrel therapy.
BEL repressed rifampicin-induced gene expression of CYP3A4 and multidrug resistance protein 1, as well as their respective protein activities.
The aim of the present study was to evaluate the association between the CYP3A4*1B gene polymorphism (rs2740574) and the risk of developing breast cancer. CONCLUSION: We have not observed a relationship between the CYP3A4*1B gene polymorphism and the occurrence of breast cancer
CYP3A4 catalyzed omega- and (omega-1)-hydroxylated MCFAs with the lowest Km and highest Vmax /Km values.
ACT-541468 has been determined as CYP3A4 substrate.
expression several hundred-fold greater in liver than in skin; expression of CYP3A5 significantly greater than that of CYP3A4 in skin
Prediction of area under the curve for a p-glycoprotein, a CYP3A4 and a CYP2C9 substrate using a single time point strategy: assessment using fexofenadine, itraconazole and losartan and metabolites.
ABCB1 C1236T, ABCB1 G2677 T/A genotype and BMI are probably the factors influencing the clinical efficacy of tacrolimus in treating patients with nephrotic syndrome.
YP3A4*1G SNP is unlikely to affect pain relief efficacy of oxycontin.
TT genotype of CYP3A4*1G (rs2242480) polymorphism was associated with increased risk of breast cancer.
No relationship between CYP3A4 activity and tacrolimus metabolite.
Studied herb-drug interactions of mistletoe extracts with endoxifen and their associations with inhibition of CYP3A4/5 and CYP2D6 in vitro.
four binding interactions of aNF to P450 3A4 are suggested by this study, one of which may be newly recognized and which could affect studies of drug oxidations by this important enzyme
We analyzed tacrolimus trough concentrations in 1345 adult EA recipients with two CYP3A5 LoF alleles in a genome-wide association study. Only CYP3A4*22 was identified and no additional variants were genome-wide significant
It was concluded that CYP3A related metabolism in horse is not solely dependent on the expression of the enzyme but also on adequate levels of NADPH P450 reductase and cytochrome b(5).
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases that catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by glucocorticoids and some pharmacological agents. This enzyme is involved in the metabolism of approximately half the drugs in use today, including acetaminophen, codeine, cyclosporin A, diazepam and erythromycin. The enzyme also metabolizes some steroids and carcinogens. This gene is part of a cluster of cytochrome P450 genes on chromosome 7q21.1. Previously another CYP3A gene, CYP3A3, was thought to exist\; however, it is now thought that this sequence represents a transcript variant of CYP3A4. Alternatively spliced transcript variants encoding different isoforms have been identified.
, P450-III, steroid inducible
, albendazole monooxygenase
, albendazole sulfoxidase
, cytochrome P450 3A3
, cytochrome P450 3A4
, cytochrome P450 HLp
, cytochrome P450 NF-25
, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 3
, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 4
, cytochrome P450-PCN1
, glucocorticoid-inducible P450
, nifedipine oxidase
, quinine 3-monooxygenase
, taurochenodeoxycholate 6-alpha-hydroxylase
, cytochrome P450, family 3, subfamily A, polypeptide 4
, cytochrome P450 3A80
, Cytochrome P450 CM3A-10
, cytochrome P450 3A21
, cytochrome P450 CYP3A12